Adjuvant cytokine-induced killer (CIK) cell immunotherapy has shown potential in improving the prognosis of hepatocellular carcinoma (HCC) patients after curative resection. However, whether an individual could obtain survival benefit from CIK cell treatment remains unknown. In the present study, we focused on the characteristics of CIK cells and aimed to identify the best predictive biomarker for adjuvant CIK cell treatment in patients with HCC after surgery. This study included 48 patients with HCC treated with postoperative adjuvant CIK cell immunotherapy. The phenotype activity and cytotoxic activity of CIK cells were determined by flow cytometry and xCELLigence™ Real-Time Cell Analysis (RTCA) system, respectively. Correlation analysis revealed that the cytotoxic activity of CIK cells was significantly negative correlated with the percentage of CD3+ CD4+ cell subsets, but significantly positive correlated with CD3-CD56+ and CD3+ CD56+ cell subsets. Survival analysis showed that there were no significant associations between patients’ prognosis and the phenotype of CIK cells. By contrast, there was statistically significant improvement in recurrence-free survival (RFS) and overall survival (OS) for patients with high cytotoxic activity of CIK cells as compared with those with low cytotoxic activity of CIK cells. Univariate and multivariate analyses indicated that CIK cell cytotoxicity was an independent prognostic factor for RFS and OS. In conclusion, a high cytotoxic activity of CIK cells can serve as a valuable biomarker for adjuvant CIK cell immunotherapy of HCC patients after surgery.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
- CIK cells:
Cytokine-induced killer cells
- RTCA system:
Real-Time Cell Analysis system
Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262
Page AJ, Cosgrove DC, Philosophe B et al (2014) Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am 23(2):289–311. https://doi.org/10.1016/j.soc.2013.10.006
Lai EC, Fan ST, Lo CM et al (1995) Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221(3):291–298
Dhir M, Melin AA, Douaiher J et al (2016) A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 263(6):1112–1125. https://doi.org/10.1097/SLA.0000000000001556
Samuel M, Chow PK, Chan Shih-Yen E et al (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev (1):CD001199 https://doi.org/10.1002/14651858.CD001199.pub2
Xiao Z, Wang CQ, Feng JH et al (2019) Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: a systematic review and meta-analysis of 32 randomized controlled trials. Cytotherapy 21(2):125–147. https://doi.org/10.1016/j.jcyt.2018.10.011
Zhu J, Li R, Tiselius E et al (2017) Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev 12:CD011300 https://doi.org/10.1002/14651858.CD011300.pub2
Zhou X, Mo X, Qiu J et al (2018) Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis. Cancer Manag Res 10:5363–5372. https://doi.org/10.2147/CMAR.S173201
Ma Y, Zhang Z, Tang L et al (2012) Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14(4):483–493. https://doi.org/10.3109/14653249.2011.649185
Schmeel LC, Schmeel FC, Coch C et al (2015) Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 141(5):839–849. https://doi.org/10.1007/s00432-014-1864-3
Chen C, Ma YH, Zhang YT et al (2018) Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy 20(8):975–989. https://doi.org/10.1016/j.jcyt.2018.06.002
Cao J, Kong FH, Liu X et al (2019) Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 25(27):3649–3663. https://doi.org/10.3748/wjg.v25.i27.3649
Lee JH, Lee JH, Lim YS et al (2015) Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148(7):1383–1391. https://doi.org/10.1053/j.gastro.2015.02.055
Lee JH, Lee JH, Lim YS et al (2019) Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother 68(1):23–32. https://doi.org/10.1007/s00262-018-2247-4
Xu L, Wang J, Kim Y et al (2016) A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology 5(3):e1083671. https://doi.org/10.1080/2162402X.2015.1083671
Pan QZ, Wang QJ, Dan JQ et al (2015) A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Sci Rep 5:9202. https://doi.org/10.1038/srep09202
Mata-Molanes JJ, Sureda Gonzalez M, Valenzuela Jimenez B et al (2017) Cancer immunotherapy with cytokine-induced killer cells. Target Oncol 12(3):289–299. https://doi.org/10.1007/s11523-017-0489-2
Schmidt-Wolf IG, Negrin RS, Kiem HP et al (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149. https://doi.org/10.1084/jem.174.1.139
Pan K, Guan XX, Li YQ et al (2014) Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res 20(11):3003–3011. https://doi.org/10.1158/1078-0432.CCR-14-0082
Pan QZ, Tang Y, Wang QJ et al (2015) Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology 4(9):e1038017. https://doi.org/10.1080/2162402X.2015.1038017
Erskine CL, Henle AM, Knutson KL (2012) Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J Vis Exp 66:e3683. https://doi.org/10.3791/3683
Messaoudene M, Fregni G, Fourmentraux-Neves E et al (2014) Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res 74(1):81–92. https://doi.org/10.1158/0008-5472.CAN-13-1303
Schmidt-Wolf IG, Lefterova P, Mehta BA et al (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673–1679
Lu PH, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153(4):1687–1696
Pan K, Li YQ, Wang W et al (2013) The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 20(13):4305–4311. https://doi.org/10.1245/s10434-013-3144-x
Zhang L, Wang J, Wei F et al (2016) Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. Oncotarget 7(28):43604–43615. https://doi.org/10.18632/oncotarget.9871
Verneris MR, Karimi M, Baker J et al (2004) Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103(8):3065–3072. https://doi.org/10.1182/blood-2003-06-2125
Li H, Yu JP, Cao S et al (2007) CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 27(3):317–326. https://doi.org/10.1007/s10875-007-9076-0
Huang L, Qiao G, Morse MA et al (2019) Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. Oncol Lett 18(6):5717–5724. https://doi.org/10.3892/ol.2019.10964
This work was primarily supported by a grant from the National Key Research and Development Program of China (No. 2018YFC1313400), the National Natural Science Foundation of China (No. 81803079; 81402560; 81572865; 81472387), the Guangdong Natural Science Foundation (No. 2018A030310237), and the Guangdong Province Science and Technology Plan Project (No. 2017A020215029).
Conflict of interest
The authors declare no conflict of interest.
The Institutional Review Board of the Sun Yat-sen University Cancer Center approved the study design (B2016-035-01). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Pan, Q., Liu, Q., Zhou, Y. et al. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother (2020). https://doi.org/10.1007/s00262-020-02486-y
- CIK cell immunotherapy
- Hepatocellular carcinoma